Vanda Pharmaceuticals | VNDA - مصروفات التشغيل





مصروفات التشغيل تغيير تاريخ
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Anika Therapeutics USD 29.97M 116.84M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 513.55M 109.86M 2025-12
J&J USD 17.44B 1.53B 2026-03
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
Merck USD 10.16B 558M 2025-12
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Moderna USD 1.54B 259M 2025-12
Novartis USD 9.8B 23M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 10.51B 1.21B 2025-12
Takeda JPY 1.02T 400.98B 2025-12
Teva Pharmaceutical Industries USD 4.22B 812M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09
Veracyte USD 116M 7.24M 2025-12